Related Experiment Videos
Inhibition of proteases in Pseudomonas otitis media in chinchillas
C S Cotter1, M A Avidano, S P Stringer
1Department of Otolaryngology, University of Florida, Gainesville, USA.
Abstract:
The treatment of chronic suppurative otitis media caused by Pseudomonas aeruginosa remains a challenging problem. The virulence of Pseudomonas is related to its secretion of two matrix metalloproteinases, alkaline protease and elastase. This experiment examines the effects of a synthetic inhibitor of matrix metalloproteinases GM 6001, or N-(2(R)-2(hydroxyamido carbonylmethyl)-4-methylpentanoyl)-L-tryptophane methylamide), in a chinchilla Pseudomonas otitis media model. Thirty chinchillas underwent bilateral subtotal tympanic membrane perforations. Twenty-four chinchillas underwent bilateral middle ear inoculation with P. aeruginosa. Chinchillas were divided into four groups of six animals after the establishment of otitis media. Animals in one group were controls; the other three groups received either gentamicin, GM 6001, or gentamicin plus GM 6001 into the external auditory canal three times daily for 4 weeks. Clearance of Pseudomonas infection occurred in three ears of three animals, all in gentamicin groups, with or without GM 6001. Otorrhea (p = 0.0014) and external canal erythema (p = 0.025) were mild in the two gentamicin groups and moderate in the GM 6001 group when compared with bacterial controls. Animals in the GM 6001 group had the highest survival rate, less severe facial paralysis, and less vestibular toxicity than the gentamicin, gentamicin plus GM 6001, or control groups, although these differences were not statistically significant. This pilot study showed encouraging results for a role of ototopical protease inhibitors in the treatment of Pseudomonas otitis media.
Insights
This study explored GM 6001, a protease inhibitor, for treating Pseudomonas otitis media in chinchillas. GM 6001 showed potential for reducing infection symptoms and toxicity, though not statistically significant.
Area of Science:
- Otolaryngology
- Microbiology
- Pharmacology
Background:
- Chronic suppurative otitis media (CSOM) caused by Pseudomonas aeruginosa presents treatment challenges.
- Pseudomonas virulence is linked to matrix metalloproteinases (MMPs), including alkaline protease and elastase.
Purpose of the Study:
- To evaluate the efficacy of GM 6001, a synthetic MMP inhibitor, in a chinchilla model of Pseudomonas otitis media.
- To assess the safety and therapeutic potential of GM 6001 as an ototopical treatment.
Main Methods:
- Chinchillas with induced Pseudomonas otitis media were treated with gentamicin, GM 6001, or a combination therapy.
- Treatments were administered ototopically for 4 weeks, with outcomes compared to a control group.
Main Results:
- Clearance of Pseudomonas infection was observed in gentamicin-treated groups, with or without GM 6001.
- GM 6001 treatment resulted in milder otorrhea and external canal erythema compared to controls.
- The GM 6001 group exhibited higher survival rates and reduced facial paralysis and vestibular toxicity, though not statistically significant.
Conclusions:
- GM 6001 demonstrates encouraging potential as an ototopical treatment for Pseudomonas otitis media.
- Further research is warranted to explore the role of protease inhibitors in managing otitis media.